UNSPSC 51386203: Eltenac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H9Cl2NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A153L3JA99, chemically known as 4-(2,6-dichloroanilino)-3-thiopheneacetic acid but generally known as eltenac, which bears US NIH Compound Identifier 51717. European Medicines Agency schedules Eltenac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06495MIG.

UNSPSC 51386203 Eltenac, a Commodity code, covers pharmaceutical products procured by state and local health agencies, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and related pharmacy benefit program support. State and local governments buy under this code to support community health initiatives, emergency response capabilities, and pharmacy benefit management for state employees and populations served by health and human services agencies. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. The scope spans direct product procurement (naloxone, OTC items), manufacturer-supplied pharmaceuticals through authorized wholesalers, and related pharmacy benefit infrastructure and pricing models.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for a Direct-to-Manufacturer Prescriptions program to support the state's pharmacy benefit objectives, with responses due the same day. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026. MMCAP requires vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson) and imposes a 3 percent administrative fee on all contract purchases.